This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Sciences (GILD) Stock Moves 0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $71.15, marking a +0.23% move from the previous day.
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
by Zacks Equity Research
Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.34, moving +0.65% from the previous trading session.
Merck (MRK) Begins Molnupiravir Study for COVID Prevention
by Zacks Equity Research
Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.
Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.
Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review
by Zacks Equity Research
Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status
by Zacks Equity Research
Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, McDonald's, Union Pacific Corp, Gilead Sciences and Uber
Top Stock Reports for Thermo Fisher, McDonald's & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), McDonald's Corporation (MCD), and Union Pacific Corporation (UNP).
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider loss on increased R&D expenses in the second quarter.
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut
by Zacks Equity Research
Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.
Q2 Earnings Beats Don't Stop Late-Market Selloffs
by Mark Vickery
Amazon (AMZN) beat earnings estimates for its Q2, but the stock is falling -6.3% in late trading.
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 6.25% and 1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare ETFs in Focus as Q2 Earnings Unfold
by Sweta Killa
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.41 in the latest trading session, marking a -1.08% move from the prior day.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $68.30, marking a +0.54% move from the previous day.
Galapagos (GLPG) Falls on Inflammatory Study Data Readout
by Zacks Equity Research
Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.